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Newman, Mackenzie. M.S., Department of Pharmacology & Toxicology, Wright State 
University, 2013. Effects of Red Diamondback Rattlesnake Venom on Keloid Dermal 
Fibroblasts In Vitro 
Keloid scarring is an inflammatory healing response to physical injury such as incision or 
piercing in the dermis. It is characterized by aberrant extracellular matrix production, the 
overaccumulation of mature collagen, and excessive fibroblast proliferation and 
migration beyond the borders of the original wound site. This results in swelling, 
depigmentation, itchiness, and pain akin to a benign tumor. Although there are myriad 
treatments for the condition, most are invasive and exhibit a high recurrence rate. 
Previous studies have shown that rattlesnake venom stimulates apoptosis in the skin via 
multiple specific mechanisms, largely composed of extracellular matrix and its receptors’ 
interactions. The goal of this study is to isolate and identify constituents of Crotalus 
ruber ruber (C.r.r.) venom that may attenuate keloid fibroblast proliferation. Snake 
venom was ultrafiltered and fractionated on a cationic column in a fast protein liquid 
chromatography (FPLC) system followed by de-ionization through dialysis membranes. 
Normal fibroblasts and keloid samples were treated with fractionated venom and assayed 
for cell proliferation and collagen production, while venom was tested for its capacity to 
deplete collagen. Separated venom composition was described via MALDI-TOF and 
further qualified by specific activity studies. Our results suggest that C.r.r. venom 
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The skin is an extremely complex organ that is the body's first defense against 
environmental factors. It is the largest organ of the human body with an average surface 
area of 1.5-2m
2
 (Seifert, 2008). The integumentary system includes all layers of the skin, 
including the epidermis, dermis, and hypodermis. The epidermis is largely composed of 
keratinocytes, the dermis of fibroblasts, and the hypodermis of fibroblasts and 
macrophages. Varieties of specialized structures dwell in the skin, including hair follicles, 
sweat glands, and nerve terminals. The largest volume of the skin, the dermis, is 
composed mainly of extracellular matrix, i.e. collagens (Alberts, 2002), with a low 
degree of vascularization.  
Wound Healing 
Wound healing is one of the oldest studied biological processes (Bhatia, 2004). It is an 
immensely complex mechanism that involves myriad cell types and growth factors. It 
occurs in three or four principle, overlapping stages, depending on source; these may be 
limited to inflammation, proliferation, and maturation (Martin 1997; Broughton, 2006; 
Seifert, 2008).  
During the first stage of wound healing, the primary goal of the injured tissue is to seal 
damaged blood vessels to attain hemostasis (Gousain, 2004). Clotting commences with 
the activation of platelets, primarily via the recognition of non-native collagens in the 




release of pluripotent cytokines such as transforming growth factor-beta (TGFβ), 
plateletactivating factor (PAF) (Parent, 1993), platelet-derived growth factor (PDGF) 
(Throckmorton, 1995) and vascular endothelial growth factor (VEGF) (Frank, 1995), and 
interleukin-1 (IL1) (Sauder, 1991). TGFβ primarily serves to induce production of 
extracellular matrix proteins and proteoglycans such as collagen, fibrin and fibronectin 
(Roberts, 1992). Platelet activating factor (PAF), a glycerophosphocholine ester, 
modulates leukocyte-driven platelet recruitment and degranulation (Topham, 1998). 
PDGF is a potent mitosis inducer that allows cells to skip the G1 restriction checkpoint in 
order to drive cellularity of the lesion that also attracts neutrophils and macrophages to 
the area (Diegelmann, 2004). IL1 promotes coagulation and helps stimulate the overall 
immune response (Sauder, 1991; Yang, 2012). Autocrine signaling in macrophages and 
neutrophils perpetuate the inflammatory phase of wound healing. 
As leukocytes recede from the active wound, signals from wound-latent VEGF prime the 
site for angiogenesis for the second phase of wound healing (Romano, 2002; Bao, 2009; 
Wilgus, 2012). The stage, often dubbed "proliferation", lasts for up to two months after 
the initial injury. Fibroblast growth factors (FGF) such as FGF-2 and FGF-7 stimulate 
keratinocyte growth and migration (Yen, 2013) to stabilize the dermis with the outer 
layers of the epidermis; this process of reepithelization is mediated by mesenchymal cells 
and macrophages by autocrine TGFβ and paracrine epidermal growth factor (EGF) and 
tumor necrosis factor alpha (TNFα) (Chen, 2008). They work along with TGFβ, which is 
now secreted primarily by macrophages, neutrophils, and fibroblasts, to encourage 
collagen type III production in fibroblasts for the formation of granulation tissue to 




wound site. More fibroblasts are generated by the actions of TGFβ and endothelin-1 on 
inactive fibrocytes to further produce matrix, matrix metalloproteases, and cytokines 
(Dawes, 1996; Reilkoff, 2011). FGFs and VEGF encourage endothelial cell growth and 
drive plasminogen activation (Mossesson, 2005). 
The final phase of healing may take years to complete. It is known as "maturation" of the 
wound and is characterized as the terminal differentiation of the site. Tissue integrity may 
approach its original tensile capacity (Hoying, 2006; Demidova-Rice, 2012). Wounds 
contract while maturing due to the action of myofibroblasts in the area; these cells exhibit 
characteristics of muscle-derived fibroblasts and secrete large amounts of collagen-I 
while depleting stocks of granular collagen-III (Hoying, 2006; Demidova-Rice, 2012). 
PDGF and TGFβare major determinants in the progress of the maturation process that 
have been shown to directly affect the remodeling capacity of fibroblasts toward the 
production of structural matrix proteins such as collagen (Fujiwara, 2005) and laminin 
(Malinda, 2008; Stroncek, 2008), glycosaminoglycans including chondroitin and 
hyaluronan (Ellis, 1992; Hoffmann, 2012), matrix metalloproteases like MMP1 
(collagenase) and MMP2 (gelatinase) (Fujiwara, 2005), and plasmin mediators such as 
plasminogen activator inhibitor-1 (PAI1), tissue urokinase (uPA), and kallikrein (Li, 
2003; Kishibe, 2012). Tight regulation of the formation and degradation of the 
extracellular matrix is crucial during the maturation phase of wound healing for proper 
dermostasis  
Scarring 
Scarring is the final endpoint of wound healing. Scar tissue, which forms throughout the 




especially mature, processed type I (Broughton, 2005).Scarring does not occur in human 
fetuses and other organisms with the appropriate regenerative capacity (Leung, 2012). 
The formation of scars has been correlated to wound duration (Vowden, 2011); because 
numerous ECM members are upregulated during healing, their overproduction is possible 
and reinforced by the prevalence of hypertrophic factors in disordered wound healing.  
Keloid Phenotype 
Keloid scarring is most often encountered as an overhealing response to dermal injury 
such as incision, piercing, or burning, though it has been observed to appear after itching, 
acne, spontaneously, and by other means (Seifert, 2008; Yi, 2013). Keloids appear more 
frequently in women than men by multiple accounts (Furtado, 2009; Gauglitz, 2011). All 
keloid scars are hypertrophic scars in nature, but not all hypertrophic scars are keloids 
(English, 1999); the ultimate characteristic of the subject is its capacity to recur after 
treatment or invade surrounding tissue (Simman, 2003; Fujiwara, 2005; Gauglitz, 2011). 
Children and elderly are less likely to form keloids than those aged 10-30 and non-white 
racial groups (Juckett, 2009). Some studies (Marneros, 2004; Nakashima, 2010; Zhu, 
2013) that focus on families and individual racial groups profile genetic loci which may 
be of pharmacological interest reveal, for example, anEGF receptorchain and the 




quality of life by those affected in multiple surveys (Bock, 2006; Furtado, 2009).
 
Figure 1: Male Earlobe Keloid Harvested for Study 
Figure 1 is an example of an earlobe keloid that developed after the removal of ear 
gauages. 
Keloid Pathology 
Keloid scars have been exhibited to possess altered amounts of numerous chemical 
species, including but not limited to salts and small radicals (Chau, 2005; Ong, 2010) , 
glycosaminoglycans (Meyer, 2000) and glycoproteins (Babu, 1989; Chung, 2011), fats 
(Huang, 2013), oncogenic products (Saed, 1998; Russell, 2010), cytokines (Seifert, 
2008), and, by definition, matrix proteins. Keloidal tissue is hypoxic (Kischer, 1992)and 
rather acellular compared to acute hypertrophic dermis (Moshref, 2010). It maintains 
more heavy metals and gelatins than normal skin (Bang, 2002) at least in part due to the 
enhanced production of matrix metalloproteases and ADAMs (Seifert, 2008; Imaizumi, 




fraying the matrix, therefore allowing mutant redifferentation. Sugar derivatives 
hyaluronic acid (Meyer, 2000; Seifert, 2008; Hoffmann, 2012) and fibronectin (Babu, 
1989; Oliver, 1992) each have been a focus in keloids for their ubiquitous dysregulation 
in affected scars for their potential to normalize TGFβsecretion and slow cell migration 
due to significant interactions with cytokines, integrins, and ECM. 
Keloids overexpress TGFβ. These scars are also commonly described with upregulated 
collagen-I (Chipev, 2000; Seifert, 2008), laminin (Lim, 2003), aggrecan (Shih, 2010), 
integrins (Szulgit, 2002),thrombins (Smith, 2008), plasmins (Tuan, 2003), and elastins 
(Smith, 2008). SMADs and matrix metalloproteases are dysregulated (Seifert, 2008). 
Excess collagens clump into amorphous semifibrillar granules that may intercalate other 
extra ECM molecules to promote disordered local adhesion. TGFβ-related pathways are 
overpromoted due to autocrine signaling in dermal fibroblasts that perpetuates ECM 





Table 1: Differential Characteristics of Overgrown Scars (Seifert, 2008) 
 
Keloid Fibroblasts 
Keloid fibroblasts are considered to be the progenitors of keloid scar pathology (Seifert, 
2008). Previous research has shown them to show markers of numerous cell types, 
including but not limited to osteocytes (Naitoh, 2005), keratinocytes (Felice, 2007), 
endothelial cells (Seifert, 2008), chondroblasts (Inui, 2011), chondrocytes (Naitoh, 2005), 
and myofibroblasts (Chipev, 2000; Seifert, 2008). These mutants appear primarily at the 
margins of scars where the lesion is spreading; fibroblasts isolated from the centers of 
keloid scars have been shown to be characteristically normal (Lu, 2007). Compared to 




2008). Both their cytoplasmic space and nuclei appear to be engorged compared to 
normal fibroblasts. Whereas normal fibroblasts are spindle-shaped with some arm-like 
projections, keloids express many acute, long, and non-arrayed appendages (Yi, 2013). 
Keloid fibroblasts may develop from senescent cells in the dermis or surrounding tissues; 
isolated cells exhibit a larger capacity to migrate and invade versus normal fibroblasts 
(Fujiwara, 2005). 
TGFβ Signaling 
Transforming growth factor-beta (TGFβ) is a cytokine that is involved in numerous 
cellular process including cell cycle regulation, differentiation, apoptosis, endosome 
formation and degradation, and embryonic development (Kanehisa, 2000; Kanehisa, 
2014). It is one of the most promulgated molecules implicated in keloid pathology (Babu, 
1992; Seifert, 2008). TGFβis upregulated in nearly all tissues normally but is especially 
present in kidney, lung, bone, and placenta (Branton, 1999). It has been shown to 
predominate in numerous fibrosis-related disorders, including liver cirrhosis, atrial 
fibrillation, pulmonary fibrosis, and keloid scarring (Ueha, 2012). The identification of 
TGFβ is attributed to Anita Roberts (Sporn, n.d.). The peptide is classified as an activin 
analogue due to its affinity for activin receptors; type I TGFβreceptorsaredescribed as 
"activin-like kinase 5" or ALK5 (Nicolas, 2003; The Uniprot Consortium, 2013). Since 
its initial isolation, TGFβhas become the titular constituent of a superfamily of proteins 
which all contain a similar cystine superstructure. Some of the key members of this group 
include nodal, activin, and bone morphogenic proteins which are implicit in neuronal and 
embryonic homeostasis (Wu, 2009). The eight reduced cysteines are connected in a 






Figure 2: TGFβ Quaternary Structure (―C‖ is cysteine; capitalization denotes 
conserved cystine in TGFβ superfamily) (Hart, 2003; The Uniprot Consortium, 2013) 
TGFβ is secreted is a propeptide into the extracellular space as a 390 residue-long chain 
that is cleaved to yield the active, 112-residue TGFβ monomer. After cleavage, TGFβ 
remains associated to its zymogen core, then known as latency associated peptide (LAP). 
The latency complex remains dormant and may be further coordinated by latent-
transforming growth factor beta-binding protein 1 (LTBP1) to prevent receptor binding. 
When complexed TGFβ is activated, for example by matrix metalloproteases, it binds a 
type II receptor dimer which phosphorylates a type I receptor dimer at a serine residue. 
Activation of a type I receptor leads to SMAD disengagement from the receptor in the 
cytoplasm and gene transcription downstream that allows the production of extracellular 
matrix proteins (Roberts, 1998). 
Integrin Signaling 
Integrins are integral membrane proteins that are a cell's primary sensors of the 
extracellular matrix. They play a role in adherence, mechanotransduction, motility, cell 
shape, and regulation of the cell cycle (Kanehisa, 2000; Kanehisa, 2014). The surface 
receptor is typically encountered a heterodimer of at least one alpha and one beta integrin 
subunit while the internal receptor exists as the association of a variety of proteins and 




MVD or KGE) recognition motif that binds sites on collagens and fibronectin to establish 
stable matrix fixation (Barczyk, 2009). Large phosphorylated complexes known as "focal 
adhesions" constitute stable integrin receptors. Detachment and dissolution of focal 
adhesions results in anoikis, a specialized form a cell death related to matrix interaction 
(Frisch, 2001). Integrins bind ECM molecules such as collagen, laminin, fibrinogen, and 
vitronectin directly (Barczyk, 2001). They also play a vital role in hemostasis; integrin 
αIIbβ3, also known as glycoprotein receptor αIIbβ3, is expressed ubiquitously on 
platelets and allows them to form a thrombus. This property has become the subject of 
medical intervention in recent years (Bledzka, 2013).  
Modern Treatments 
Scars have been treated with a gamut of medicines throughout history. The most frequent 
initial treatment for keloid scars today is corticosteroid injection. Excision is a common 
secondary treatment but may be avoided due to the prevalence of recurrence associated 
with it. Chemotherapy drugs, radiation therapy, silicone gel sheeting, cryosurgery, and 
experimental therapeutics appear often in literature as alternative remedies (Simman, 
2003; Juckett, 2009; Hunasgi, 2013). One relevant clinical trial recorded the effects of 
bacterial collagenase injected into keloid scars; all patients suffered from gross necrotic 
lesions (Kang, 2006). Others focus on the use of unsaturated fatty acids, including those 
derived from snake oil, to reduce scarring (Datubo-Brown, 1990); historical, anecdotal 
evidence both supports and dissuades the legitimacy of the use of snake oil as a scar 
remedy (Louw, 2000; Louw, 2006). Among all the scar treatments described in the 
literature, all are far from perfect with respect to disease recurrence (Simman, 2003; 





Snake venom is a mixture of proteins and peptides that are evolutionarily targeted toward 
the capture and digestion of prey. It is produced exclusively in a modified salivary gland 
and is secreted through a specialized ductal-fang delivery system to be delivered to its 
target. The proteomic components in snake venom exhibit a plethora of biological 
activities, such as anticoagulation (Bledzka, 2013), extracellular matrix cleavage 
(Teixeira, 2005), hemorrhage (Mori, 1987a), platelet activation (Bledzka, 2013), 
thrombus dissolution (Morais-Zani, 2009), angiogenic stimulation (Masaki, 1998), 
mitosis via growth factors (Momic, 2011), cell membrane disruption (Mayer, 1993; 
Rádis-Baptista, 2011), generation of peroxide (Torii, 1997), ion channel disfigurement 
(Dutertre, 2010), and DNA breakdown (Dhananjaya, 2010), and ATP depletion (Kini, 
1982). Snake venom also contains numerous short peptides, nucleic acid derivatives, and 
organic compounds that are purported to function as inhibitors of the enzymes in venom, 
including but not limited to tripeptides (Munekiyo, 2004), nucleotides and nucleosides, 
and citrate (Mackessy, 2009). 
All snakes have a common ancestor. The evolution of venom composition is tightly 
connected to the prey of the snake. Similarly, as snakes age, the size of prey correlates to 
that of the predator. Snakes dwell in nearly all habitats across the planet, with the 
exception of arctic regions. All snake venoms contain highly targeted neurotoxins, 
cytotoxins, myotoxins, and hemotoxins. Most of the toxins the produce the former three 
functions act non-enzymatically. Neurotoxic venom components target acetylcholinergic 
synapses and ion channels, while cytotoxins and myotoxins bind ion channels, 




Hemotoxic venom components are often encountered as enzymes that lyse blood 
components and prevent proper thrombus formation in wound healing (Mackessy, 2009). 
Snake Venom Therapeutics 
Snake venom is an ideal focus for therapeutics because it is targeted toward mammalian 
tissue. Research into the uses of venom began, largely, in the 1970s and 1980s, with a 
surge in development of rapid proteomic screening tools including FPLC and HPLC. One 
of the initial snake venom derivatives to make it to market in the United States was 
captopril, an early ACE inhibitor (Smith, 2003). It was developed using QSAR in a 
similar fashion to tirofiban, another venom drug and the first to be designed through this 
mode. Tirofiban is an anticoagulant that binds platelet integrin αIIbβ3 (Bledzka, 2013). 
Eptifibatide, a cyclopeptide based on southeastern pygmy rattlesnake venom, exhibits the 
same mechanism of action (Bledzka, 2013). Three high-profile proteases from snake 
venom that have been investigated for use in the United States include ancrod (Lowe, 
1982), batroxobin (Hao, 2012), and fibrolase (Markland, 2010). Each is described for its 
affinity to cleave fibrinogen and its ability to produce a blood clot; these drugs are 
implemented as anticoagulants when interference cannot be encountered in platelet 
signaling. Study endpoints for the first two were met and the drugs are marketed today; 
the third could not pass phase III trials for peripheral arterial occlusion and central venous 
accession. Other venom components have been explored in biological systems for 
therapeutic potential (Jain, 2010; Kurozumi, 2012; Marangoni, 2013) but none have made 





Red Diamondback Snake & Venom 
Table 2: Snake Venom Peptides (Harvey, 2006; Mackessy, 2009) 
 
Crotalus ruber ruber, colloquially ―red diamondback rattlesnake‖, is the nominate 
subspecies of rattlesnake that is indigenous to the southwestern United States and 
northern Mexico (Straight, 1992). It is a considerably long snake that is characterized as 
producing large volumes of venom (Mackessy, 1985). This red-hued rattlesnake's venom 
shares many characteristics of that of Crotalus spp. including sharp proteolytic activity 
and ECM-binding properties (Mackessy, 1985; Mori, 1987a; Hamako, 2007). It is 
considered to produce weaker biological reactions than that of many other rattlesnakes 
(Hamako, 2007; Komori, 2011), but this property is compensated in nature by the snake's 
large size which allows more venom to be delivered. Proteolytic activity in venom is 
typically higher in adults and snakes in captivity (Mackessy, 2009; Komori, 2011).  
Table 3: Previously Identified Proteins and Peptides in Crotalus ruber Venoms 
(Mackessy, 1985; Mori, 1987a; Mori, 1987b; Takeya, 1990; Straight, 1992; Takeya, 





The venom of Crotalus ruber subspecies has been assayed for numerous properties and 
many proteins and peptides have been sequenced; a summary of these is provided in 
Table 3. Notably, a report by Mackessy describes L-amino acid oxidase activity in C.r.r. 
venom and evidence from our laboratory and other crotalid sequences suggests that at 
least one unsequenced protein similar to apoxin-I exists in C.r.r. venom. 
Ruberlysin 
A major constituent of C.r.r. venom is ruberlysin, a zinc- and calcium-dependent SVMP 
characterized as inducing hemolysis and necrosis in experimental settings. Ruberlysin is a 
mildly acidic ~23,321Da protein.  It shares homology and identity with many human 
matrix metalloprotease, ADAM (A disintegrin and metalloprotease), and ADAMTS 
(ADAM with thrombospondin motifs) gene products (Altschul, 1990). Residues 153-155 
of ruberlysin are KGD (Komori, 2011; The Uniprot Consortium, 2013) which 
functionally act like a traditional RGD motif to bind collagens, integrins, and other ECM 




Table 4: Specific Cleavages of Various Substrates by Ruberlysin (Schomburg, 2013)
 
The malleability of the active site of ruberlysin is revealed by various studies on the 
specific activity of ruberlysin-containing fractions of snake venom: this SVMP appears to 
possess both hydrogen-bonding and nonpolar binding affinity sectors; see Table 4 for 
details. Ruberlysin was initially denoted as HT-2 by Stephen P. Mackessy for the median 
MW fraction determined by SDS-PAGE. This toxin, along with HT-1 and HT-3, resolved 
as one of the venom's three major peak-fractions after HPLC and gel filtration by 
absorbance intensity at 280nm (Mackessy, 1985). All fractions possessed hemorrhagic 
properties and the first two have been sequenced (Takeya, 1990; Takeya, 1993). There is 
some disagreement about the N-terminus of ruberlysin: one source reports glutamine 
(The Uniprot Consortium, 2013) in the sequence while another reports a post-translation-
modified form, pyroglutamate (Takeya, 1990). A second, modified ruberlysin-like SVMP 
has been sequenced and characterized from C.r.r.; rubelase differs from ruberlysin by 






The most prominent keloid characteristics are collagen accumulation and production and 
increased fibroblast lifespan. Rattlesnake venom is comprised of a number of proteins 
and components that normally act synergistically to produce the desired effect in its prey. 
Venom components that bind and/or cleave collagens and/or ECM constituents are likely 
to directly influence the pathways associated with the proliferation of keloid fibroplasias. 
Rattlesnake venom has been shown to stimulate apoptosis in myriad cell types via a 
variety of cell-specific mechanisms. These mechanisms include but are not limited to 
interactions with the ECM and its receptors, ion carrier disturbance, and membrane 
disruption. Due to the unknown nature of the constituents of C.r.r. venom on keloid 
fibroblasts, it is necessary to characterize these proteins and peptides and their relevant 
properties in order to sieve toward a disease treatment. 
The hypothesis is that the separation and identification of these whole venom constituents 
by mechanical means will allow a more detailed analysis of the potential of specific 
components for therapeutic use. Additionally, the application of these Crotalus ruber 
ruber venom components to keloid dermal fibroblasts will elicit more pronounced effects 
to phenotypic and proliferative properties compared to those of normal human dermal 
fibroblasts.  
Specific Aim 1 






Specific Aim 2 
Evaluate the ability of separated C.r.r. venom to cause proliferation or death on keloid 
scar and normal dermal fibroblasts. 
Specific Aim 3 
Determine the efficacy of separated venom components at reducing keloid fibroblast 
phenotypic characteristics such as collagen production. 
Specific Aim 4 







II. MATERIALS AND METHODS 
1. Venom Collection 
Crotalus ruber ruber venom was manually procured in the laboratory of animal research 
at Wright State University every two weeks. The snake was fed at the end of each two-
week period and its terrarium was tended between venom collections. Two sterile 
Eppendorf tubes were covered with fresh parafilm and aligned in front of a red 
diamondback snake's fangs. The snake handler, Dr. Sharath Krishna, held the snake from 
behind its head and teased it into secreting venom into the containers by waving a 
sacrificed mouse in front of its face. The collected product was quickly transported to 
Central State University on ice, lyophilized overnight, and stored at -20ºC until further 
use.  
2. Venom Rectification 
Desiccated, frozen venom (around 10mg) was dissolved in one milliliter of distilled, 
deionized water (ddH2O) using a Millipore Academic Milli-Q system. For some 
experiments, this was rectified into filtrates and insolubles through 10K, 30K, or 50K 
molecular weight cutoff filters (Millipore, catalogue UFC501024 (10K), UFC503024 
(30K), UFC505024 (50K)) before FPLC treatment. The resultant solutions were 
processed using a Bio-Rad DuoFlow FPLC System which employed 100mM 
tris(hydroxymethyl)aminomethane (Tris) (A) and 100mM Tris plus 500mM NaCl (B) as 
buffers, each adjusted to pH 7.6 using concentrated hydrochloric acid. After sample 




between the buffers for 13mL at 4mL/minute. At the same rate, isocratic flow was 
resumed with 100% (B) for 10.8mL and then 100% (A) for 15mL at the end of the 
process. Thirty one-milliliter fractions were collected in total.  
 
Figure 3: Apparatus for Venom Dialysis 
Figure 3 displays the methodology used for venom dialysis: the lids, including hinges, 
were removed from 1.5mL microfuge tubes with a razor blade (Figure 3C), making sure 
to smooth the edge of the tube tops (Figure 3D and Figure 3E). The fractions which 
possessed significant absorbance at 214nm were immediately transferred into these 
microfuge tubes. Cellulose dialysis membrane (―Spectra/Por6‖ 1kD MWCO, Spectrum 
Labs, catalogue 132636) was sectioned, stretched over the top of each tube (Figure 3F), 
and secured around the edge with 5/16" elastic bands (Figure 3G). The tubes were then 
inverted to test for leaks and placed into individual vials of deionized, distilled water 
(Figure 3H). The dialyzing units were allowed to stand for one hour in order fully 




The de-salted venom fractions were then deposited into 1.5mL microfuge tubes and 
frozen at -20ºC for future experiments. 
3. Identification of Venom Components 
3.1 Whole Fraction Digestion 
The protocols for Sigma product T6567 were adapted for these procedures. Fifteen 
microliters of 50mM ammonium bicarbonate solution were mixed with 1.5μL of 100mM 
dithiothreitol in a 0.5μL microfuge tube and followed by 25μL of venom fraction. The 
mixture was reduced at 95ºC for five minutes in a water bath while 100mM 
iodoacetamide was prepared in a foil-wrapped tube. Three microliters of the latter were 
added to the cooled samples and incubated in the dark at room temperature for 20 
minutes. Trypsin stock was prepared at a concentration of 0.1g/L from proteomics grade 
porcine pancreatic trypsin (Sigma, catalogue T6567) and two microliters were added to 
each tube. Samples were digested overnight at 30ºC and immediately processed by the 
protocols described in 3.3.1. 
3.2 Component Digestion 
3.2.1 SDS-PAGE Electrophoresis 
Twenty microliters of Laemmli sample buffer 2X (Bio-Rad, catalogue 161-0737) with 
five percent 2-mercaptoethanol were added to 20μL of sample and this was boiled in a 
0.5mL microfuge tube for five minutes. The then-darkened samples were allowed to cool 
to room temperature and all forty microliters were pipetted into 4-20% Tris-HCl gels 
(Bio-Rad, catalogue 345-0032). Protein stacking was observed for twenty minutes at 
100V and separation was performed at 180V for forty-five minutes. After ceasing the 




placed in a clean blotting box on an undulating shaker. It was gently swirled with 25mL 
of deionized, distilled water for five minutes, fluid was pipetted from the box, and then 
the proteins were fixed with 25mL of a 50% acetic acid/7% methanol solution for fifteen 
minutes. Fixing solution was discarded and the remnants were washed away with three 
five-minute interval water exchanges. The gel was then stained for 45 minutes using 
GelCode Blue Safe Protein Stain (Thermo Scientific, catalogue 24594) and excess stain 
was washed away by another set of water exchanges. Resolute bands from the finalized 
gel were selected and cut out with a razor for further processing. These individual bands 
were used immediately in the methodology described in 3.2.2 or stored overnight at 20ºC.  
3.2.2 In-Gel Digestion 
The methods of Shevchenko et al. (2007) were adapted for these procedures.  
Ammonium bicarbonate at a 50mM concentration (C) was used to prepare stock buffers 
of 25mM ammonium bicarbonate (D) and 1:1 50mM acetonitrile (ACN)/ammonium 
bicarbonate (E). One hundred microliter aliquots of (C) were added to tubes containing 
the stained protein bands from 3.2.1 and let stand for 10 minutes. Supernatant was 
discarded before 50μL of (E) was added and drawn off twice in ten-minute intervals. The 
gel band was dried in a centrifugal evaporator for five minutes while 10mM dithiothreitol 
was dissolved into (D). This solution was added in 20μL lots to the tubes and samples 
were heated at 37ºC for 60 minutes. Fresh 55mM iodoacetamide was prepped in (D) then 
added in 20μL quantities to the cooled samples. Incubation in the dark was permitted for 
45 minutes at 37ºC. After the tubes reached room temperature, 100μL of (D) were used to 
wash the gel for 10 minutes. The fluid was sucked away before 100μL of (E) was inserted 




minutes to ensure full dehydration of the gel disk. Sequencing grade trypsin was brought 
to a 20mg/L density in (D). Fifteen microliters were added to each tube along with 15μL 
of (D). Samples were digested overnight at 37ºC. Fluid was then removed after 
centrifugation, 20μL of 0.3% trifluoroacetic acid (TFA) was pipetted directly onto the gel 
band, and three extractions were performed with a 50% ACN/0.3% TFA mixture for ten 
minutes each. The volume of the collected supernatant was reduced to 10μL via vacuum 
centrifuge. The final samples were stored at -20ºC until processed by the protocols of 
3.3.1. 
3.3. Mass Spectrometry 
3.3.1 Protein Preparation 
The resultant peptide mixtures from 3.1 and 3.2.2 were prepared for mass spectrometry 
using C18 ZipTips (Millipore, catalogue ZTC18M096). A series of five 1.5mL tubes was 
prepared for each sample including one of pure acetonitrile, two of 0.1% TFA, one with 
95% ACN/0.3%TFA, and an empty tube for sample collection. ZipTip procedures by 
Amanda Freeman were then followed directly. After purification, unknown samples were 
mixed 1:1 with 10mg/mL CHCA and 1μL was spotted onto a 384-well ground steel plate. 
3.3.2 MALDI-TOF Parameters 
A Bruker Daltronics Autoflex III Smartbeam MALDI-TOF mass spectrometer was used 
in conjunction with components of the Autoflex software (including Flexcontrol, 
Flexanalysis, and Biotools) to obtain all mass spectrometry data. The system was 
calibrated with Peptide Standards II (Bruker Daltronics), omitting data points with an 
error rate greater than 0.015Da
-1
, before each use. Default method protocols for MS and 




for MS collection, 90% for parent ion identification, and 100% for protein fragmentation. 
Data were passed through the MASCOT and Swissprot database servers set exclusively 
to search metazoan datasets against a monoisotopic distribution with two or fewer partial 
(missed) cleavages, potential oxidation at methionine residues as the sole variable 
modification, a mass tolerance of 400ppm, an MS/MS tolerance of 1.0Da, and a charge 
state of +1. Peaks of interest were selected from the derived spectra using the Bruker 
SNAP processing parameter algorithm with a signal-to-noise threshold of 6 and quality 
factor threshold of 50. 
4. Peptide Cleavage Assay 
Buffers and substrate concentrations suggested in the description for Sigma product 
F5135 were used as guidelines for these experiments. FALGPA (N-[3-(2-Furylacryloyl)]-
L-leucyl-glycyl-L-prolyl-L-alanine) (Crescent Chemical Company, catalogue 51565.01) 
was dissolved at 5μg/mL and 1μL was added with 1μL of 0.36mM calcium chloride and 
50mM HEPES at pH 7.0 to 10μL of each snake venom fraction. Aliquots of the reactions 
were placed in sealed Eppendorf tubes in a 37ºC dark incubator for 45 minutes. Reactions 
directly spotted for MALDI-TOF using standard CHCA matrix. 
5. In Vitro Studies 
5.1 Cell Isolation and Expansion 
Wright State University IRB SC#4833was written and filed for these experiments. 
Dermal samples were acquired from the earlobe ofa consenting African American male, 
age 24, under care in the private office of Dr. Richard Simman. KF1 cell line was 




"Skin specimens were first washed with phosphate-buffered saline (PBS) (Gibco, Life 
Technologies
TM
, USA) three times to exclude erythrocytes, then cut into 2.5mm x 2.5mm 
pieces and incubated with 2ml digestion medium containing high glucose Dulbecco's 
Modified Eagle's Medium (DMEM) (Gibco, Life Technologies
TM
, USA),5 mg/mL 
collagenase/dispase II (RocheDignotics, USA) and 0.25% trypsin (Invitrogen, Life 
Technologies
TM
, USA) in 60x15mm tissue culture dish for 8h at the condition of 5% 
CO2, at 37
o
C.Then the tissue suspension was passed through a 100 mm filter 
(BiologixResearch Company, USA) to remove any remaining tissue residuals. The 
suspension was next centrifuged at 300 G for 8 min to obtain cell pellet. This pellet was 
transferred to a T25 cell culture flask cultured with 3 ml total medium containing high 





, USA) in the  condition of 5% CO2, at 37
o
C. Cells took 
approximately 3 days to totally attach to the bottom and reach to confluence in about 10 
days. After cells were attached the bottom of the flask, total medium was replaced with 
fresh total medium. During cell growth, every 2 or 3 days medium was changed after 
PBS washing to exclude the flatting dead cells. Once reaching confluence (named as 
Passage 1) cells were detached into a new passage by 0.05% trypsin (Invitrogen, 
LifeTechnologies
TM
, USA)." [sic] (Yi, 2013) 
Normal fibroblasts (NF) were cultured from frozen samples of isolated cells from dermal 
tissue of an African American female of similar age to the primary specimen. Keloid 
fibroblast cells, derived from a 35-year-old African American female, referred to as KF2, 
were purchased from ATCC (product CRL-1762). They were notably late-generation (at 




storage at the company. All fibroblast cell lines were maintained in routine culture using 
DMEM modified with glucose (4.5g/L), glutamine, and antibiotics (streptamycin, 
amphotericin, and penicillin). Consecutive cultures were passaged with 0.25% trypsin 
(Mediatech Cellgro, catalogue 25-050-Cl) using untreated DMEM for washing and full 
media for quenching. Incubation followed standard protocol of 5% CO2 and 37ºC 
exposure in darkness. 
 
5.2 Fibroblast Proliferation Assays 
NF, KF1, KF2, and cells were raised to ~80% confluency in T75 flasks before 
trypsinization and plating with nystatin-containing complete DMEM into 8-well chamber 
slides. Five slides of each cell type were prepared and allowed to reach full confluency or 
slightly overgrow in order to ensure appropriate cell quorum for microscopy. Media was 
replaced with 150μL previously-prepared venom dilutions in serum-free DMEM (1e-6 
original concentration) and the slides were covered and incubated for six hours at 37ºC 
under 5% CO2. 
5.3 MTT Assay 
Normal fibroblasts were incubated overnight in 96-well plates at a cell density on the 
order of 1e5 cells/mL. All reagents were prepared from a stock kit (―TACS(R) MTT Cell 
Proliferation Assays‖, Trevigen, catalogue 4890-50-K). Snake venom stock was prepared 
at one-half original concentration in DMEM and a 1:10 serial dilution of this was made 
down to 1e-7 the initial stock. Media was aliquoted to each well to adjust to a total 
volume of 150uL/well after venom addition. Plain media was used as a control. After 3 




dark cell culture incubator for three hours. After noting the appearance of purple coloring 
in the wells, the plates were removed from the incubator and left overnight in the dark at 
room temperature. Plates were read in a plate reader for their absorbance at 535nm. 
5.4 Collagen Integrity Assay 
The methods of Walsh et al. (1992) were modified for these protocols. Cells were plated 
in 96-well microplates with lids and allowed to settle overnight in complete media. Serial 
filtered venom fractions were prepared at 1e-6 their original concentrations in DMEM 
and applied to cells after removing original media. After four hours’ incubation at 37ºC 
under 5% CO2, the plates were immediately placed in a-20ºC freezer and well contents 
were allowed to solidify overnight. The following morning, lids were removed and the 
plates were wrapped loosely in foil and left overnight in a dry incubator at 37ºC. Wells 
were rinsed three times for one-minute increments with 200μL of distilled water. 
Picrosirius red dye was prepared by the addition of Direct Red 80 (Sigma, catalogue 
365548) to saturated picric acid solution at a 0.1% (w/v) concentration and 100μL was 
added to each well for one hour. The wells were rinsed five times with 200μL of 10mM 
HCl at 10 seconds per exposure and then 200μL of 0.1M NaOH for 5 minutes. The 
stained collagen slurry was gently mixed ten times up and down in a pipettor and 
transferred to a new plate for absorbance measurement under a 535nm filter.  
5.5.1 van Gieson Staining 
The methods of Ellis (2013) and Hunasqi (2013) were modified for these experiments. 
Hoescht 33258 was diluted from stock, hemotoxylin was used directly from stock, and 




S. Nuclei were first bound by Hoescht for 90 minutes and then hemotoxylin was applied 
for five minutes. After, Curtis' stain was applied for five minutes to stain collagens. All 
dyes were aliquoted into 150μL volumes for each sample and reactions were carried out 
at 37ºC, under CO2, in the dark. All wells were carefully rinsed between stains with 






After the final histological solution was flushed, 4% paraformaldehyde was added to each 
well for 30 minutes at 4ºC. The chambers were then removed from the slides and each 
was rinsed in ddH2O. Fluorogel with Tris buffer (Electron Microscopy Sciences, 
catalogue 17985-10) was applied to coverslips which were immediately affixed to the 
slides. A Leica DMR B microscope operated with Leica TASv3.7 software was 
employed for all microscopy. Due to physical restrictions, differentiation between 
Ponceau S and picrosirius dyes was not detectable so photographs were recorded only for 
Hoescht and picrosirius.  
5.6 Quantitative Proliferation Assay 
All cell lines were individually seeded in 96-well plates in duplicate for the following 
procedures. Fibroblasts were allowed to grow past full confluency in order to ensure 
appropriate population and matrix density and encourage mild senescence as present in 
keloidal tissues.  Venom fractions at 1e-6 the original concentration in plain media were 
applied in 100μL aliquots to fibroblast cells for four hours in duplicate. After removing 
the treated media and rinsing the wells twice with ddH2O, propidium iodide (10μg/mL) 
was applied for thirty minutes in the dark at room temperature. Plates were read in a 
Packard Fusion microplate reader for fluorescence using an excitation filter at 600nm and 








Develop a strategy to mechanically separate proteins and peptides from red 
diamondback venom 
 
Figure 4: Workflow for Experiments 
The workflow used for all experiments is displayed in Figure 4. After separation 
treatments (red; Aim 1), venom was tested for cell responses (purple; Aim 2), collagen-





Figure 5: FPLC Output after Injection of RDB Venom 
Figure 5 shows the absorbance of the FPLC effluent at 214nm, an indicator of peptide 
bond concentration, and the fractions chosen for further testing. Fractions exhibiting 
resolute peaks in noticeable concentration were selected. Fractions F, G, J, and K each 






Figure 6: SDS-PAGE Gel of 10K, 30K, and 50K Filtered Venom 
Figure 6 is an SDS-PAGE separation of RDB venom after the application of different 
MWCO filters. RDB venom distilled into resolute classes of peptides. The band around 
17kDa is most likely a hemorrhagic toxin, based on early protein gel recovery 
experiments (data not shown). The dark band present in both the 50K and 30K filter tops 
was unidentifiable via mass spectrometry but suspected to but some form of HT3 given 





Figure 7: FPLC Output for Venom Separated via Serial Filtration 
Figure 7 shows the FPLC outputs for each post-filtration venom separation. The injection 
peaks (the first major peak) in the 10K and 30K diagrams have been scaled out of the 
picture in order to accent the differences in the minor peaks. Separation is not visible 
given the height of the injection peak. Differential absorbance at 214nm (AU; displayed 





Figure 8: Composite of FPLC Output of Venom Separated via Serial Filtration 
Figure 8 shows the relative quantitative protein distribution about the samples passed 
through the FPLC. A similar pattern of amplitudes is present in all runs but the 
distribution of prominent intensities varies per filtration, implying that different products 
are concentrated at different points throughout the filtration process. The height of the 
injection peak (the first major peak, truncated in the figure due to size constraints) 
changes considerably between the samples due to reduced venom density after successive 






Evaluate the ability of separated C.r.r. venom to cause proliferation or inhibition on 
keloid scar and normal dermal fibroblasts 
 
Figure 9: Spectrophotometric Absorbance of MTT Dye at 535nm after Serial 
Dilution Venom Exposure at Three Hours 
MTT assay is a measure of cell viability: the dye is a bulky, sterically-hindered, optically-




results from serial venom dilution exposures, displayed in Figure 9, suggest a mixed 
response from fibroblast cells. The untreated group showed a similar response in all 
lanes. Color change implying inhibition of cells or the induction of oxidoreductive 
signaling—an overall trend downward—was observed in fractions A, C, D, F, and G. The 
last two fractions showed sharp responses at the lowest doses used. Proliferation was 
suggested by the absorbances recorded from exposure to fraction H. Fractions B, E, and I 
exhibited scattered effects. A difference in one aberrant point from each of these datasets 





Figure 10: Normal Fibroblasts Exposed to Venom at Various Concentrations over a 
1-Day Period 
Enzyme contamination is evidenced by the effect of the venom fractions depicted in 




spindle-like arms were degraded along with broad surface features of intact ECM, and 
acellular debris was accounted at numerous time points in each fraction. Fraction 2 
possessed little visible activity, while fractions 3 through 7 caused noticeable fibroblast 
detachment and degradation within one hour. Fractions 8 and 9 displayed lytic activity 
but some recovery was noted at the end of the 24-hour exposure period; after one day of 
treatment, the cells appeared to clump and regenerate their arms. Similar effects were 







Figure 11: Cells Exposed to 10K, 30K, or 50K MWCO Filtered Venom at Varied 
Concentration 
Figure 11 shows the effect of filtered venom in serial dilution on normal fibroblasts 
afterfour hours. This was performed in order to determine an appropriate dose at which 
the cells showed minimal effect. The macroscopic effects are not identical between 
dosages, but the overall trend was similar: from high to low exposure, cells detached, 
rounded, and tended to float in large, clumped groups, then floated separately, eventually 
remaining adherent to the surface of the plate but retaining their rounding. The lowest 
doses did not affect the extended fibrous arms of the cells and eventually allowed for 
cells to remain grouped on the plate. The lowest exposure, 1e-6 the original venom 
concentration, was selected as the safest dosage range observed; a minimal or no effect 




After four hours of venom exposure, fibroblasts, stained for their nuclei and collagen 








Figure 12: Pictures of Cells Exposed to Venom Fractions from 10K MWCO Filter 
and Stained for Collagen and Nuclear Information 
Compared to controls, some cell lines showed stronger responses over others. For 10K 
filtered venom, Figure 12, normal fibroblasts clumped with fractions 3 and 8 and cell 
density rose after exposure to fractions 5, 8, and 16. KF1 cells' nuclei shrank after 








Figure 13: Pictures of Cells Exposed to Venom Fractions from 30K MWCO Filter 
and Stained for Collagen and Nuclear Information 
Fractions from the 30K filter exhibited effects primarily on normal and young keloid 
cells (Figure 13). Fractions 3, 14, 15, and 16 increased density of normal fibroblasts, 
while fraction 17 induced clumping. Fractions 8 and 15 lowered seed density and fraction 
18 removed all visible cells from the culture. Fraction 13 increased cell density. No 





Figure 14: Pictures of Cells Exposed to Venom Fractions from 50Kb MWCO Filter 
and Stained for Collagen and Nuclear Information 
Few effects were noted from the fractions that resulted from the bottoms of the 50K filter 
(Figure 14). KF1 cells were absent from culture after exposure to fraction 3 and fractions 







Figure 15: Pictures of Cells Exposed to Venom Fractions from 50Kt MWCO Filter 
and Stained for Collagen and Nuclear Information 
The 50K filter fractions had effects on all cell types (Figure 15). Clumping was observed 
in fractions 3, 14, and 21 in the normal fibroblast line. KF1 cell density was lowered by 
fractions 8, 16, and 21, while only acellular debris could be detected after exposure to 








Figure 16: Cell Staining with Propidium Iodide after Four Hours Exposure to 
Snake Venom 
Cells exposed to dilute snake venom fractions for four hours showed a multitude of 
responses in terms of propidium iodide absorbance as a marker of proliferation; these 
reactions in terms of percent change are plotted in Figure 16. Dye absorbance was 
normalized to a control for each cell line. No fractions were observed to negatively affect 
both keloid lines while simultaneously preserving the normal fibroblast line. 
Considerable proliferative effects were observed in the young keloid line (KF1) for many 
fractions. Eleven venom components appeared to inhibit the early-stage keloids while 
allowing other lines to thrive. These fractions—4 from 10K, 4, 9, and 16 from 30K, 4, 11, 
and 13 from the 50K bottom, and 3, 11, and 14 from the 50K top—were selected for 




Determine the efficacy of separated venom components at reducing keloid fibroblast 
phenotypic characteristics such as collagen production 
 Figure 17: MS of FALGPA Digests of 10K Filter Venom 
FALGPA, a known collagenase substrate, was chosen for these experiments due to its 
commonplace use in determining collagenase activity in unknown enzyme mixtures. The 
theoretical molar mass of pure FALGPA is 476.53Da. When FALGPA with buffer was 
assayed on the mass spectrometer directly, this peak was entirely absent. A mass at 




considered to be the substrate and may represent the monosodium salt. A representative 
spectrum is in Figure 17. Figure 17 displays the digest spectra from the 10K MWCO 
filtered venom and Figures 36, 37, and 38 (Appendix 1) contains the FALGPA digest 
spectra from the 30K, 50Kb, and 50Kt filtered venoms. The standard’s mass intensity at 
500Da was not found to change after samples were subjected to incubation under assay 
conditions. A drastic change in the mass intensity at this peak was used as a reference for 
collagenase activity. Although mass spectrometry is a semi-quantitative technique at best, 
a sharp change in peak height—on the order of ten-thousands of AU—provides a reliable, 
strict boolean as to whether the peptide was cleaved. The substrate was regarded as 
degraded by all fractions. Attempts were made to couple the loss of the peak at ~500Da 
to a gain in some smaller peptide. A mass appeared around 104Da in all fractions which 
was not present in the control. The only amino acids with masses around this value, with 
regard to the potential addition of sodium ion, are cysteine and threonine, which are not 
present in FALGPA. Literature states that bacterial collagenase breaks the substrate 
solely between the leucine and glycine residues, resulting in hydrolysis product masses of 
~244Da and ~250Da. These masses or the addition of these to small group I cations were 
not observed by the SNAP algorithm. However, given the nonspecific nature of known 
snake venom enzymes, it is possible that substrate hydrolysis did not cease in the same 





Figure 18: Quantitative Collagen Integrity after 4 Hours Venom Exposure 
Fractions which exhibited a negative change over KF1 but a positive effect over the other 
cell lines were selected from propidium exposure tests to be assayed for their effect on 
collagen integrity; Figure 18 is plot of the results. The untreated controls possessed 
similar collagen levels between the normal and second keloid fibroblast lines. The 
amount of bound Sirius red dye bound by the cell lysates was the least in the NF line and 
most in KF2 for all fractions except for 13 from 50Kb and 14 from 50Kt. All snake 
venom fractions reduced the integrity of collagens in fraction normal fibroblasts. The 
amount of bound dye increased notably in fraction 16 from the 30K filter bottom and 





Identify proteins and peptides from fractionated snake venom 
 
Figure 19: Mass Spectrum of Trypsin-Digested Whole Venom 
Figure 19 shows the mass spectrum of whole RDB venom after trypsin treatment. Few 
major peaks resolved from the digest. No significant peaks resolved above the range 
displayed. According to theoretical digests of RDB proteins based on literature sources, 
whole venom contains more resolute peaks than those recorded from our whole venom. 
Mascot database identified the venom as containing the protein putative secreted protein 
(Q6MYF5_ASPFU; Aspergillus fumigates, Sartorya fumigate) with a significance score 
of 60 based on the peptides, while the Uniprot databank searched under the same 
conditionsidentified the venom as containing the protein polyferridoxin protein vhuB 
(VHUB_METVO; Methanococcusvoltae) with a significance score of 54. A score of 78 






Figure 20: Mass Spectra of Venom Fractions 
Figure 20 displays the mass spectra of the fractions after trypsin digestion. Fractions A, I, 
J, and K were similar as were B and C, and G and H in terms of resolved masses; see 
Appendix 3 for specific values. Fractions D and F appeared to contain relatively 
abundant, singular digested peptides, at 828.452 and 533.179Da, respectively. The latter 





Figure 21: Mass Spectra of Ultrafiltered Venom 
Figure 21 shows distinct profiles of post-trypsin-cleaved proteins resulting from the 
ultrafiltration of RDB venom. The same derived masses that passed through the filters, 
such as 1165 and 2154, and the retained mass of 1405, were consistent among all three 
runs, while each fraction possessed unique peaks that were not observed in the other runs, 
such as 2251 in the top (retentate) of the 10K filter, 2405 in the bottom (permeate) of the 






Figure 22: Mass Spectra of FPLC-Processed Fractions from 10K Filter from 600-
1100Da and 1100-4500Da 
Figure 22 shows the mass spectra of venom after ultrafiltration through a 10K filter, 




or 650 and 855 or 861Da with the exception of fragments 7, which contains neither, and 2 
and 5, which do not contain the high-MW peptides. A mass around 523Da was observed 
in fractions 1, 7, and 10. Fractions 5, 7, 9, 10, and 11 gave little contrast in the mass 
spectrometer above 1100Da. A mass around 1189Da was measured in fractions 2, 3, 4, 6, 
and 8. Fractions 1 and 2, the injection peaks, contained mass intensities around 1276 and 
1485.  
Figures 25 and 26 (Appendix 1) show the mass spectra of venom after ultrafiltration 
through a 30K filter, FPLC processing, trypsinization, and ziptipping. Barring the fifth 
fraction, all separations possessed intense masses around 644 or 650, 702, and 855 or 
861. Fraction 4 has a 1046Da peak in noticeable quantity, and fractions 2, 5, and 7 have a 
623 peak varied within the range of a small number of electron masses. Many of the 
spectra are flat above 1100Da, though an 1189 peak was observed in fraction 1. Unique 
masses were recorded in fractions 2, 4, 5, 8, 10, and 11, but most lacked stark contrast 
overall.  
Figure 27 and 28 (Appendix 1) show the mass spectra of venom after ultrafiltration 
through a 50K filter, FPLC processing, trypsinization, and ziptipping. All fractions 
selected in this range possess peaks around 644 and 855 or 861 and, except for the sixth, 
one at 702. Fraction six shares a peak around 689 with fraction five and has a unique 
peak at 893. 
Figure 29 and 30 (Appendix 1) show the mass spectra of venom that was retained in the 
top of a 50K filter after ultrafiltration, FPLC processing, trypsinization, and ziptipping. 




rest contained masses at 644 or 650, 689 or 702, and 855 or 861. Fraction 3 had a peak 
around 1189, fractions 1, 4, 5, and 7 had a peptide around 1246, and fractions 1, 2, 4, and 
5 each had one around 1679. The rest of the samples provided weakly-contrasted spectra. 
 
Figure 23: Comparison of Fraction 3 (Injection Peak) from Venom Filtrations 
Notably different masses resolved between the various fraction volumes from the FPLC, 
considering that the conditions at which the machine was ran were the same per trial. The 








 fractions (Figure 23 and Figures 
31, 32, 33, 34, and 35; Appendix 1) were quite distinct; those in the others were similarly 
distributed. The 30K and 50Kb cutoffs filtered like mass profiles in the injection effluent, 







Figure 24: Representative Mass Spectra of LIFTs Performed on Venom Fractions 
Figures 24 and Figure 39(a-c) (Appendix 1) displays the LIFTs performed on prominent 
peaks found in refined, digested C.r.r. venom. The distances between the initial peaks in 
the 855, 861, and 877Da LIFTs were similar, as were those between 1060 and 1066, and 




fractions within a 1Da tolerance included 175 in 1933, 1943, 1964, 2186, and 2316, 704 
in 889 and 893, 750 in 4198 and 4312, 871 in 1060 and 1249, 889 in 1585, 2709, and 
3315, 1758 in 1933 and 1943, and 3485 in 4198 and 4312. Intermediate peaks which 
were identified by the default Bruker LIFT method that matched parent masses within a 
1Da tolerance included 855 in 1047, 861 in 889, 877 in 1066, 889 in 1585, 893 in 1268, 
1060 in 1249, 1287 in 2709, and 2187 in 2316. LIFTs performed below 855Da produced 






Table 5: Proteins Identified in Fractions Indicated via MALDI-TOF with Statistical 
Significance 
 
Few coupled MALDI-TOF and LIFT datasets provided statistically-significant evidence 
that the venom fractions contained previously-characterized and sequenced proteins in 
MSDB and the Swissprot database. Table 5 contains the significant data and Table 6 
(Appendix 2) contains data from earlier database searching that used a broad mass 
tolerance of 800ppm. The only fractions to contain these proteins were in the top of the 
50K filter and all of them were identified as ruberlysin. Because ruberlysin’s mass is 
~24kDa, it is possible that there is either at least one similar metalloprotease in the venom 
with a high molecular weight such as the one previously named ―HT-3‖ or that 
ruberlysin’s size restricts it from passing through the 30K and 50K filters efficiently. 
Both the injection fraction (fraction 3) and others that passed through the FPLC indicated 
ruberlysin as well, implying that the protein quantity is high enough to contaminate more 
samples than the restrictions set by the physical limitations of the buffer system can 
overcome. Many other fractions from all filtrations possessed masses that matched or 




databases. Some of these masses include 1192Da, 1246Da, and 1679Da. Theoretical 








Develop a working scheme to isolate single proteins and peptides from red 
diamondback venom 
The combination of ultrafiltration and FPLC results in a cost- and time-effective 
partitioning system for snake venom proteins and peptides. Sample mixtures can be 
reliably resolved into components within hours, depending on the rate of buffer dialysis 
after FPLC treatment.  
After one passage through our FPLC, mild separation of proteins and peptides was 
attained. The mass spectra of the ten fractions showed two basic fragment profiles and all 
of them returned similar results after database searching [Newman, 2012]. Simple 
ultrafiltration of snake venom showed consistent separation of proteins and peptides: the 
same fragments were observed after trypsinization after passage through filters, e.g. a 
fragment around 1405Da resolved in the bottom of the 30K and 50K filter but not the 
10K filter, when sizing membranes were the only mode of separation employed. 
When the techniques were used in tandem, this patterning does not appear to be so clear-
cut. This may be due to the presence of multiple snake venom metalloproteases of 
different size classes in red diamondback venom: the active site is heavily conserved and 
the trypsinized fragment is likely to be similar or the same among most venom 
metalloproteases, but the complete secreted protein may already be partially cleaved by 
the venom itself during in vivo processing and secretion or laboratory handling of the 




concentrates the sample into a solid that brings all components into direct contact with 
one another. Similarly, the usage of buffers during separation provides charged and steric 
cofactors that may modulate the proteolytic activity implicit in red diamondback venom. 
The presence of serine proteases and the nonspecific action of SVMPs coupled to their 
dimer- and trimer-forming sites may allow early destruction of whole proteins. PII, PIII, 
and PIV SVMPs are described as long-chain metalloproteases with individually-active 
moieties such as lectins, phospholipase A2s, and disintegrins. A few specific sites on 
long-chain metalloprotease may be preferentially autolyzed during venom production and 
this process may result in the sequestration of these moieties as individual proteins. For 
example, myotoxin (Swissprot accession P24330) shows a high homology when queried 
against snake metalloproteases (The Uniprot Consortium, 2013). However, the individual 
moieties present in the metalloproteases in C.r.r. venom may not necessarily fall prey to 
this type of cleavage; instead, structural damage may result to the quaternary structure of 
the intact protein. 
Evaluate the ability of separated C.r.r. venom to cause proliferation or death on 
keloid scar and normal dermal fibroblasts. 
Many effects were observed after the application of C.r.r. venom to dermal fibroblasts. 
MTT assay provided evidence of cell inhibition in all fractions and time-response 
photography showed signs of inhibition or loss of cells in all fractions. Some of the 
effects were immediate and others were gradual; this may be purely to the quantity of 
venom in each fraction. One technique used in literature to determine concentration is 
based on the absorbance output from FPLC separations, but this measurement requires at 




not reliably detect protein in a single fraction. The same effects of the time-response—
initial exposure leading to cell rounding and floating, living cells adhered back to the 
plate, regenerated their spindles, and spread out across the wells—were observed from a 
high to low venom dose. Quantitative propidium iodide staining gave mixed results in 
that no fractions appeared to minimally or positively impact normal fibroblasts while 
perturbing both keloid lines. The most prominent effects were observed over the young 
keloid fibroblast line. These effects were reinforced by the results gathered by 
photography of all three cell lines after staining for nuclear information and collagen: few 
living cells or only debris was left after exposure to the most fractions. Normal 
fibroblasts, which exhibited a high endogenous density and replication rate, showed the 
most positive changes toward proliferation. 
 
Determine the efficacy of separated venom components at reducing keloid fibroblast 
phenotypic characteristics such as collagen production. 
Our intention in testing the capacity of our venom to break down collagen was so that we 
could verify the absence or presence of metalloproteases in the venom. Although serine 
proteases may cleave collagen, this activity has not been described inC.r.r. venom up to 
this point and was not considered during study. FALGPA was chosen for initial studies 
due to its prevalence in the characterization of collagenolytic activity of bacterial 
collagenases used in research. Few fractions completely degraded the 500Da peak that 
our studies attributed to FALGPA entirely but all reduced its intensity to near-zero. 
Because mass spectrometry does not perform accurate quantitative measurement and 




is not a clear-cut indicator of the absence or presence of metalloproteases. However, 
given our results from literature review, venom component identification, and results 
from collagen activity assay from whole cells, it is reasonable that all fractions may 
contain at least some trace but significant amount of metalloprotease. 
 
Identify proteins and peptides from fractionated snake venom.  
LIFT analysis of whole venom and its constituents provided a variety of data after query 
against the Swissprot and MASCOT databases. Numerous vertebrate toxins, including 
skin-derived non-human antimicrobial peptides, primate defensins, and snake 
metalloproteases were returned but none of the former and few of the latter came back 
with statistical significance. A preliminary set of data is provided in Table 6 (Appendix 
2) and a finalized chart of statistically significant data is provided in Table 5 (Appendix 
1). The only metalloprotease to be clearly defined after LIFT was ruberlysin. 
Some of the peaks observed after FPLC separation that were analyzed by LIFT were not 
clearly defined in the fractions. The parent spectra of these sequences, such as that 
derived for a peak between 1165 and 1169 in fractions 4, 5, 8, 16 in from the 10K filter, 9 
and 13 from the 50K bottom, and 11 from the  50K top were nondescript about the ranges 
when tested at one-dalton intervals. A peak at 1165 was selected as parent because it 
produced the cleanest spectrum and may have altered the search algorithm parameters 
significantly. 
The abundance of these fragments among multiple fractions may imply the presence of 
sequentially different constituent peptides. A standard isotopic distribution is typically 




red diamondback venom having been described as containing an alternatively-spliced or 
mutant metalloprotease, which differs from ruberlysin by four amino acids and the 
numerous other small chain-variant snake venom proteins that have been established in 
literature, it is possible that the fractions containing unidentifiable parent fragments carry 
alternative forms of similar sequences. Similarly, the fragmentation spectra of numerous 
parent ions show a variety of degenerate masses that may show missed cleaves by trypsin 
or single amino acid substitutions; these are detailed in the "results" section. It is 
entropically favorable for isosteric or physiochemical homologous masses to aggregate 










The red diamondback venom used in our studies contains proteins and peptides that have 
not been sequenced previously and are not present in the databases used in our search. 
Peptide fragments at or close to those which are generated after trypsin digest, such as 
that at 1585Da, that are present in multiple fractions of our venom have not been 
described in any red diamondback literature to our knowledge. However, our search 
proved fruitless in sequencing the entirety of one of these novel proteins. Ruberlysin, the 
only protein to be identified significantly, appeared in the top of the 50K filter, but its 
mass should have forced it to pass through during 30K and 50K ultrafiltration processes. 
The separation techniques employed in this study were limited in grasp but showed a 
cost- and time-effective means of efficiently separating the contents of complex protein 
mixtures. Future work on this end of the project may include refining the FPLC buffers 
and their mixing rates within the system, adding a metalloprotease inhibitor to the venom 
that does not affect trypsin, such as 1,10-phenanthroline, and further testing the activity 
of the fractions to verify the presence or absence of metalloprotease. A longer FPLC 
separation using a taller column may account for these errors outright. 
The development of a fast spectrophotometric assay for metalloprotease presence would 
be useful for future the rapid screening of separated venom. Attempts made using 




The cells used in this study gave valuable results with regard to how different types of 
dermal fibroblasts react to enzymatic subjugation. The age of the cells, i.e. how long they 
had been isolated in culture may be a relevant focus for future keloid research with regard 
to snake venom. Many snake venom fractions, especially those which showed minimal 
effect on normal fibroblast cells and pronounced effects on the keloids, may be of 
pertinent interest for therapeutic use; in this vein, longer time-response trials are required 
to eke out the real potential of the venom. All of the photographs of cells give a direction 
for the time and dose required of the venom proteins and peptides, but much more 








APPENDIX 1: RESULTS 
 













Figure 27: Mass Spectra of FPLC-Processed Fractions from 50Kb Filter from 600-
1100Da 
 






Figure 29: Mass Spectra of FPLC-Processed Fractions from 50Kt Filter from 600-
1100Da 
 






Figure 31: Comparison of Fraction 4 MS from Venom Filtrations 
 
Figure 32: Comparison of Fraction 8 MS from Venom Filtrations 
 






Figure 34: Comparison of Fraction 14 MS from Venom Filtrations 
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